STOCK TITAN

Attovia Therapeutics (ATTO) director receives 27,000 stock options expiring 2036

(Neutral)
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Attovia Therapeutics, Inc. reported that director Mitchell Gold received a grant of 27,000 stock options to buy common stock at an exercise price of $17.00 per share. The options expire on August 3, 2036. According to the award terms, 25% of the options vest on August 4, 2027, with the remaining options vesting in equal monthly installments over the following 36 months, subject to continued service.

Positive

  • None.

Negative

  • None.
Insider GOLD MITCHELL
Role Director
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) F1 27,000 $0.00 $0.00
Holdings After Transaction: Stock Option (Right to Buy) — 27,000 shares (Direct)
Footnotes (1)
  1. F1. 25% of the options shall vest on August 4, 2027 and the remaining options shall vest in equal monthly installments over the following 36 months, subject to continued service to the Issuer through such dates.
Stock options granted 27,000 options Stock Option (Right to Buy) grant to director Mitchell Gold
Exercise price $17.00 per share Conversion or exercise price of the stock option award
Options held after grant 27,000 options Total derivative securities directly owned following the reported transaction
Expiration date August 3, 2036 Expiration date of the granted stock options
Initial vesting tranche 25% on August 4, 2027 First portion of options that vest, subject to continued service
Remaining vesting period 36 months Remaining options vest in equal monthly installments over 36 months
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
exercise price financial
"conversion_or_exercise_price: 17.0000"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"25% of the options shall vest on August 4, 2027"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
derivative financial
"transaction_type: derivative"
A derivative is a financial contract whose value depends on the price or performance of another asset or measure — for example a stock, index, interest rate, commodity, or currency. Investors use derivatives like insurance or leveraged bets to hedge risk, speculate, or gain exposure without owning the underlying asset; they can protect portfolios but also amplify losses and introduce counterparty and market risk.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What did Mitchell Gold report in this Form 4 for ATTO?

Mitchell Gold reported a grant of 27,000 stock options for Attovia Therapeutics (ATTO). These options allow him to buy common stock at a fixed $17.00 exercise price before they expire on August 3, 2036.

What is the exercise price of the new stock options for ATTO?

The granted options have an exercise price of $17.00 per share. This means Mitchell Gold can purchase Attovia Therapeutics common stock at $17.00 per share once the options vest and before their August 3, 2036 expiration.

How many Attovia Therapeutics (ATTO) options did Mitchell Gold receive?

Mitchell Gold received 27,000 stock options for Attovia Therapeutics common stock. All 27,000 options are reported as directly owned following the transaction, subject to the specified vesting schedule through August 4, 2027 and the subsequent 36 months.

What is the vesting schedule for Mitchell Gold’s ATTO stock options?

The options vest over time: 25% of the 27,000 options vest on August 4, 2027. The remaining options then vest in equal monthly installments over the next 36 months, conditioned on continued service to Attovia Therapeutics.

When do Mitchell Gold’s Attovia Therapeutics stock options expire?

The stock options expire on August 3, 2036. After that date, any unexercised portion of the 27,000 options at the $17.00 exercise price will lapse, assuming they have vested according to the award’s schedule.

Are the ATTO options reported by Mitchell Gold part of a 10b5-1 trading plan?

The filing indicates the Rule 10b5-1 checkbox is not marked, and there is no footnote describing a trading plan. The grant is reported simply as a stock option award subject to time-based vesting and continued service.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
GOLD MITCHELL

(Last)(First)(Middle)
C/O ATTOVIA THERAPEUTICS, INC.
1091 INDUSTRIAL ROAD, SUITE 310

(Street)
SAN CARLOS CALIFORNIA 94070

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Attovia Therapeutics, Inc. [ ATTO ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/04/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$1708/04/2026A27,000 (1)08/03/2036Common Stock27,000$027,000D
Explanation of Responses:
1. 25% of the options shall vest on August 4, 2027 and the remaining options shall vest in equal monthly installments over the following 36 months, subject to continued service to the Issuer through such dates.
/s/ Steven Chan, Attorney-in-Fact08/06/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)